Table 2.
Description of patient data collected per extracted tooth in the oncologic and study groups
| Characteristic | Oncologic | Control | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Number of extracted teeth, n | 87 | 106 | |||||||
| Development of osteonecrosis, n (%) | MRONJ+ | MRONJ- | Total | p-value | NA | p-value | |||
| 33 | 37.9% | 54 | 62.1% | 87 | |||||
| Extraction indication, n (%) | Caries | 20 | 48.8% | 21 | 51.2% | 41 | 0.338 | 45 | <0.001 |
| Periodontitis | 11 | 34.4% | 21 | 65.6% | 32 | 16 | |||
| Fracture | 0 | 0% | 2 | 100% | 2 | 11 | |||
| Root remnant | 2 | 22.2% | 7 | 77.8% | 9 | 25 | |||
| Pericoronitis | 0 | 0% | 1 | 100% | 1 | 7 | |||
| NA | 0 | 0% | 2 | 100% | 2 | 2 | |||
| Type of teeth, n (%) * | Incisors + canines | 6 | 28.6% | 15 | 71.4% | 21 | 0.843 | 30 | 0.643 |
| Premolars | 11 | 57.9% | 8 | 42.1% | 19 | 21 | |||
| Molars | 16 | 34% | 31 | 66% | 47 | 55 | |||
| Arch, n (%) | Maxilla | 14 | 29.8% | 33 | 70.2% | 47 | 0.140 | 68 | 0.201 |
| Mandible | 19 | 47.5% | 21 | 52.5% | 40 | 38 | |||
| Region, n (%) | Anterior maxilla | 3 | 27.3% | 8 | 72.7% | 11 | 0.221 | 18 | 0.459 |
| Posterior maxilla | 11 | 30.6% | 25 | 69.4% | 36 | 50 | |||
| Anterior mandible | 3 | 30% | 7 | 70% | 10 | 12 | |||
| Posterior mandible | 16 | 53.3% | 14 | 46.7% | 30 | 26 | |||
| Antibiotic prophylaxis, n (%) | Yes | 30 | 36.1% | 53 | 63.9% | 83 | 0.151 | 20 | <0.001 |
| No | 3 | 75% | 1 | 25% | 4 | 86 | |||
| Antiseptic mouthwash, n (%) | Yes | 33 | 37.9% | 54 | 62.1% | 87 | 1.000 | 106 | 1.000 |
| No | 0 | 0% | 0 | 0% | 0 | 0 | |||
| Use of L-PRF, n (%) | Yes | 24 | 33.8% | 47 | 66.2% | 71 | 0.166 | 4 | <0.001 |
| No | 9 | 56.3% | 7 | 43.8% | 16 | 102 | |||
| Time until mucosal healing, n (%) | 0–≤4 weeks | 0 | 0% | 26 | 100% | 26 | NA | 99 | <0.001 |
| >4–≤8 weeks | 0 | 0% | 28 | 100% | 28 | 7 | |||
| >8 weeks | 33 | 100% | 0 | 0% | 33 | 0 | |||
| Mean (weeks)* | 42.8 | 4.09 | 14.19 | <0.001 | 2.41 | <0.001 | |||
| MRONJ worse stage, n (%) | Stage 1 | 21 | 63.6% | NA | NA | NA | NA | NA | |
| Stage 2 | 10 | 30.3% | NA | NA | NA | ||||
| Stage 3 | 2 | 6.1% | NA | NA | NA | ||||
L-PRF, leukocyte- and platelet-rich fibrin; MRONJ, medication-related osteonecrosis of the jaws; NA, not applicable.
The p-values described under oncologic and control correspond to those obtained with the χ2/Fisher’s exact test or Mann–Whitney U test when data were ordinal (*).
Comparisons were made between MRONJ+ and MRONJ-sites, and study and control groups.
Significant p-values (p ≤ 0.05) are italicized.